RECEPTA Biopharma
Recepta Biopharma is a Brazilian biotechnology company dedicated to research and development of new drugs for cancer treatment. Founded in 2006 through a partnership with the Ludwig Cancer Research Institute, the company focuses on developing monoclonal antibodies and peptides with potential therapeutic applications in oncology. Recepta Biopharma aims to provide innovative and affordable cancer treatments for the Brazilian population, leveraging Brazil's scientific and technological advantages in biopharmaceutical development. The company has a proven capacity to establish and successfully manage alliances and partnerships with various agents in the pharmaceutical sector, both private and public. Its mission is to discover new molecules, develop, and conduct clinical trials with monoclonal antibodies and peptides to offer more effective cancer treatment options with fewer side effects, using Brazil's scientific expertise to innovate and export high-value technology, contributing to reducing social and economic costs caused by cancer.
Industries
Nr. of Employees
small (1-50)
RECEPTA Biopharma
São Paulo, Sao Paulo, Brazil, South America
Products
Targeted antibody-drug conjugate candidate (oncology, clinical-stage)
Antibody-based targeted therapeutic candidate developed via external ADC conjugation platforms and progressed into clinical development for solid tumors.
Clinical-stage immunomodulatory monoclonal antibodies
Monoclonal antibody candidates developed as immunomodulators/checkpoint-targeting agents and advanced into clinical trials.
Therapeutic peptide candidates
Peptide therapeutic candidates demonstrated to delay tumor progression in preclinical models and advanced through patenting and preclinical testing.
Targeted antibody-drug conjugate candidate (oncology, clinical-stage)
Antibody-based targeted therapeutic candidate developed via external ADC conjugation platforms and progressed into clinical development for solid tumors.
Clinical-stage immunomodulatory monoclonal antibodies
Monoclonal antibody candidates developed as immunomodulators/checkpoint-targeting agents and advanced into clinical trials.
Therapeutic peptide candidates
Peptide therapeutic candidates demonstrated to delay tumor progression in preclinical models and advanced through patenting and preclinical testing.
Services
Preclinical research services for antibodies and peptides
Design and execution of biochemical, biophysical and functional preclinical studies (in vitro and in vivo) to assess efficacy, safety and pharmacology of antibody and peptide candidates.
Clinical trial protocol development and trial management
Preparation of clinical protocols, regulatory registration support and management of multicenter oncology trials including site coordination across hospital networks.
Cell line generation and upstream biologics development
Creation of stable mammalian producer cell lines and processes to support antibody production for preclinical and early clinical supply, including readiness for technology transfer to pilot manufacturing.
Analytical and tissue reactivity testing
Immunohistochemistry and analytical assays to determine biomolecule reactivity across tissue panels and to quantify biochemical/biophysical properties.
Partnerships, licensing and technology transfer support
Strategic advisory and deal execution for licensing agreements, technology transfer and collaborative R&D partnerships, including experience out-licensing clinical-stage antibody programs to international development partners.
Preclinical research services for antibodies and peptides
Design and execution of biochemical, biophysical and functional preclinical studies (in vitro and in vivo) to assess efficacy, safety and pharmacology of antibody and peptide candidates.
Clinical trial protocol development and trial management
Preparation of clinical protocols, regulatory registration support and management of multicenter oncology trials including site coordination across hospital networks.
Cell line generation and upstream biologics development
Creation of stable mammalian producer cell lines and processes to support antibody production for preclinical and early clinical supply, including readiness for technology transfer to pilot manufacturing.
Analytical and tissue reactivity testing
Immunohistochemistry and analytical assays to determine biomolecule reactivity across tissue panels and to quantify biochemical/biophysical properties.
Partnerships, licensing and technology transfer support
Strategic advisory and deal execution for licensing agreements, technology transfer and collaborative R&D partnerships, including experience out-licensing clinical-stage antibody programs to international development partners.
Expertise Areas
- Therapeutic monoclonal antibody development
- Peptide therapeutics discovery and development
- Preclinical in vitro and in vivo pharmacology
- Clinical trial design and multicenter trial management (oncology)
Key Technologies
- Monoclonal antibody engineering
- Antibody humanization
- Antibody-drug conjugate (ADC) platform integration
- Peptide design and chemical synthesis